Sanofi/Regeneron Deal History & Licensing Activity
Sanofi/Regeneron is a life sciences. Over the past three years, Sanofi/Regeneron has been involved in 5 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
2
Active Trials
50
Top Modality
Other
Focus Area
Autoimmune
Sanofi/Regeneron Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Sanofi/Regeneron in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| NanoDisc platform | Sanofi | Other | Preclinical | license | May 2026 |
| AI platform and pipeline expansion (including HXN-1001) | Sanofi | Other | Phase 2 | collaboration | Jun 2025 |
Sanofi/Regeneron Pipeline Focus
Therapeutic areas and modalities where Sanofi/Regeneron is most active based on deal history and clinical trial data.
Therapeutic Areas
Sanofi/Regeneron Clinical Pipeline
Sanofi/Regeneron has 50 active clinical trials across 6 development phases.
13
Unknown
4
Phase 4
3
Not Applicable
5
Phase 1
9
Phase 2
16
Phase 3
See How Your Asset Matches Sanofi/Regeneron's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Sanofi/Regeneron Licensing & Deal Activity
Sanofi/Regeneron is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, Sanofi/Regeneron ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Sanofi/Regeneron include Autoimmune (15 deals and trials), Metabolic (6 deals and trials), Infectious (5 deals and trials), and Gastroenterology (4 deals and trials). In terms of modality, Sanofi/Regeneron has shown particular interest in other, bispecific antibodies, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Sanofi/Regeneron and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Sanofi/Regeneron's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.